Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Immatics NV (IMTX)

Immatics NV (IMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Immatics: Q1 Earnings Snapshot AP - Tue May 14, 6:13AM CDT

Immatics: Q1 Earnings Snapshot

IMTX : 12.35 (-1.36%)
Immatics: Q3 Earnings Snapshot AP - Tue Nov 14, 2023

Immatics: Q3 Earnings Snapshot

IMTX : 12.35 (-1.36%)
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors PR Newswire - Tue Sep 12, 2023

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

IMTX : 12.35 (-1.36%)
PLX : 1.1100 (+0.91%)
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics ACCESSWIRE - Mon Sep 11, 2023

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules

MRNA : 122.50 (+1.12%)
IMTX : 12.35 (-1.36%)
Immatics: Q2 Earnings Snapshot AP - Thu Aug 17, 2023

Immatics: Q2 Earnings Snapshot

IMTX : 12.35 (-1.36%)
Immatics: Q1 Earnings Snapshot AP - Tue May 16, 2023

Immatics: Q1 Earnings Snapshot

IMTX : 12.35 (-1.36%)
Why Immatics Stock Is Soaring Today Motley Fool - Tue May 2, 2023

Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.

IMTX : 12.35 (-1.36%)
Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases Business Wire - Thu Mar 16, 2023

Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further development of its designer recombinases, a novel gene editing platform to transform...

IMTX : 12.35 (-1.36%)
Immatics: Q3 Earnings Snapshot AP - Thu Nov 17, 2022

Immatics: Q3 Earnings Snapshot

IMTX : 12.35 (-1.36%)
Immatics Announces Second Quarter 2022 Financial Results and Business Update Globe Newswire - Tue Aug 9, 2022

ACTengine® TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: IMA203 monotherapy at provisional recommended Phase 2...

IMTX : 12.35 (-1.36%)

Barchart Exclusives

1 Reliable Dividend Stock to Buy at a Discount This July Barchart - Mon Jul 22, 6:30PM CDT
Here’s a dividend-paying gem trading at an attractive valuation, which investors can consider this July while it's still a bargain. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot